Rivaroxaban

GPTKB entity

Statements (44)
Predicate Object
gptkbp:instanceOf gptkb:anticoagulant
factor Xa inhibitor
gptkbp:antidote gptkb:Andexanet_alfa
gptkbp:approvedBy gptkb:FDA
gptkb:EMA
2011 (US)
gptkbp:ATCCode gptkb:B01AF01
gptkbp:bioavailability 80–100%
gptkbp:brand gptkb:Xarelto
gptkbp:CASNumber 366789-02-8
gptkbp:chemicalClass oxazolidinone derivative
gptkbp:contraindication active pathological bleeding
severe hepatic impairment
gptkbp:developedBy gptkb:Bayer
gptkbp:discoveredBy gptkb:Bayer_HealthCare
gptkbp:eliminationHalfLife 5–9 hours (young), 11–13 hours (elderly)
gptkbp:excretion urine
feces
gptkbp:form gptkb:tablet
oral suspension
gptkbp:hasMolecularFormula gptkb:C19H18ClN3O5S
https://www.w3.org/2000/01/rdf-schema#label Rivaroxaban
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction inhibits factor Xa
gptkbp:metabolism liver (CYP3A4, CYP2J2, CYP-independent)
gptkbp:patentExpired 2024 (US)
gptkbp:pregnancyCategory C (US)
B3 (Australia)
gptkbp:proteinBinding 92–95%
gptkbp:riskFactor increased bleeding with other anticoagulants
not recommended in patients with prosthetic heart valves
gptkbp:routeOfAdministration oral
gptkbp:sideEffect gptkb:anemia
nausea
bleeding
dizziness
gptkbp:synonym gptkb:BAY_59-7939
gptkbp:usedFor prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis
treatment of pulmonary embolism
prevention of venous thromboembolism after orthopedic surgery
gptkbp:WHOModelListOfEssentialMedicines yes
gptkbp:bfsParent gptkb:Bayer_HealthCare
gptkbp:bfsLayer 6